Slew Of Side Events At World Health Assembly: Focus On Health Security, SDGs 22/05/2017 by Elise De Geyter for Intellectual Property Watch Leave a Comment The 70th annual World Health Assembly kicked off today with the focus of thousands on the grand plenary hall in United Nations headquarters in Geneva. But in the surrounding rooms and buildings in and outside of the UN, a wide array of side events is taking place. IP-Watch’s Global Health Policy News took a look at a selection of these events and found this year a stronger focus has emerged on the subject of health security and the new UN Sustainable Development Goals (SDGs). These are occurring alongside the usual disease-specific events and those on various sectors of humanity, the focus on access to medical products, and a variety of other current topics.
Taiwan Lobbies For Invitation To World Health Assembly, China Firmly Bars The Way 22/05/2017 by Catherine Saez, Intellectual Property Watch 3 Comments Taiwan will not be allowed to participate in the World Health Assembly (WHA) this year as an observer, the WHA has decided on its opening day. Some hours earlier today, Taiwan’s minister of health gave a press conference to denounce the fact that the country has not been invited by the World Health Organization, and saying that Taiwan needs the WHO, and the WHO needs Taiwan.
No Free Lunch, G20 Health Ministers Find At First Meeting 20/05/2017 by Monika Ermert for Intellectual Property Watch 3 Comments Group of 20 health ministers today finished their first joint table top exercise to simulate the outbreak of a new deadly viral pandemic in “Anycountry” and passed a seven-page final resolution on pandemic preparedness and antimicrobial resistance. Non-governmental experts and health organizations welcomed the first ever meeting of health ministers in the G20 format, but see a risk of framing the debate from a global North security perspective. And despite a call of urgency with regard to antimicrobial resistance, the G20 could not agree to include the de-linking of the cost of investment in R&D from the price of medical products.
Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week.
Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say 19/05/2017 by Elise De Geyter for Intellectual Property Watch Leave a Comment Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion.
G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 by Monika Ermert for Intellectual Property Watch Leave a Comment Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow.
March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 by Steven Seidenberg for Intellectual Property Watch 17 Comments It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices.
Major Research Funders, Institutions Pledge Transparency In Clinical Trials 18/05/2017 by Intellectual Property Watch Leave a Comment More transparency on clinical trials is expected after major research funders, research institutions, and international health groups agreed that the research they fund or support will publicly release results of clinical trials.
New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 by Intellectual Property Watch Leave a Comment Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries.
Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus.
